Patchen Bonnie K, Clark Andrew G, Gaddis Nathan, Hancock Dana B, Cassano Patricia A
Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.
Department of Molecular Biology and Genetics, Cornell University, Ithaca, New York, USA.
BMJ Nutr Prev Health. 2021 May 4;4(1):213-225. doi: 10.1136/bmjnph-2021-000255. eCollection 2021.
To investigate causality of the association of serum vitamin D with the risk and severity of COVID-19 infection.
Two-sample Mendelian randomisation study.
Summary data from genome-wide analyses in the population-based UK Biobank and SUNLIGHT Consortium, applied to meta-analysed results of genome-wide analyses in the COVID-19 Host Genetics Initiative.
17 965 COVID-19 cases including 11 085 laboratory or physician-confirmed cases, 7885 hospitalised cases and 4336 severe respiratory cases, and 1 370 547 controls, primarily of European ancestry.
Genetically predicted variation in serum vitamin D status, instrumented by genome-wide significant single nucleotide polymorphisms (SNPs) associated with serum vitamin D or risk of vitamin D deficiency/insufficiency.
Susceptibility to and severity of COVID-19 infection, including severe respiratory infection and hospitalisation.
Mendelian randomisation analysis, sufficiently powered to detect effects comparable to those seen in observational studies, provided little to no evidence for an effect of genetically predicted serum vitamin D on susceptibility to or severity of COVID-19 infection. Using SNPs in loci related to vitamin D metabolism as genetic instruments for serum vitamin D concentrations, the OR per SD higher serum vitamin D was 1.04 (95% CI 0.92 to 1.18) for any COVID-19 infection versus population controls, 1.05 (0.84 to 1.31) for hospitalised COVID-19 versus population controls, 0.96 (0.64 to 1.43) for severe respiratory COVID-19 versus population controls, 1.15 (0.99 to 1.35) for COVID-19 positive versus COVID-19 negative and 1.44 (0.75 to 2.78) for hospitalised COVID-19 versus non-hospitalised COVID-19. Results were similar in analyses using SNPs with genome-wide significant associations with serum vitamin D (ie, including SNPs in loci with no known relationship to vitamin D metabolism) and in analyses using SNPs with genome-wide significant associations with risk of vitamin D deficiency or insufficiency.
These findings suggest that genetically predicted differences in long-term vitamin D nutritional status do not causally affect susceptibility to and severity of COVID-19 infection, and that associations observed in previous studies may have been driven by confounding. These results do not exclude the possibility of low-magnitude causal effects or causal effects of acute responses to therapeutic doses of vitamin D.
研究血清维生素D与新型冠状病毒肺炎(COVID-19)感染风险及严重程度之间关联的因果关系。
两样本孟德尔随机化研究。
基于人群的英国生物银行和阳光联盟全基因组分析的汇总数据,应用于COVID-19宿主遗传学倡议全基因组分析的荟萃分析结果。
17965例COVID-19病例,包括11085例实验室确诊或医生确诊病例、7885例住院病例和4336例重症呼吸道病例,以及1370547名对照,主要为欧洲血统。
通过与血清维生素D或维生素D缺乏/不足风险相关的全基因组显著单核苷酸多态性(SNP)进行基因预测的血清维生素D状态变异。
COVID-19感染的易感性和严重程度,包括重症呼吸道感染和住院情况。
孟德尔随机化分析有足够的效力检测到与观察性研究中所见相当的效应,但几乎没有证据表明基因预测的血清维生素D对COVID-19感染的易感性或严重程度有影响。使用与维生素D代谢相关基因座中的SNP作为血清维生素D浓度的基因工具,与总体对照相比,血清维生素D每增加1个标准差,任何COVID-19感染的比值比(OR)为1.04(95%置信区间[CI]0.92至1.18),住院COVID-19患者与总体对照相比为1.05(0.84至1.31),重症呼吸道COVID-19患者与总体对照相比为0.96(0.64至1.43),COVID-19阳性与COVID-19阴性相比为1.15(0.99至1.35),住院COVID-19患者与非住院COVID-19患者相比为1.44(0.75至2.78)。在使用与血清维生素D具有全基因组显著关联的SNP(即包括与维生素D代谢无已知关系基因座中的SNP)的分析以及使用与维生素D缺乏或不足风险具有全基因组显著关联的SNP的分析中,结果相似。
这些发现表明,基因预测的长期维生素D营养状态差异不会因果性地影响COVID-19感染的易感性和严重程度,先前研究中观察到的关联可能是由混杂因素驱动的。这些结果不排除低强度因果效应或维生素D治疗剂量急性反应的因果效应的可能性。